HOME >> MEDICINE >> NEWS
St. Jude leukemia therapy overcomes differences in treatment outcome between black, white children

(MEMPHIS, TENN.--October 14, 2003) Investigators at St. Jude Children's Research Hospital have found that black children are equally likely as white children to benefit from improved treatment for acute lymphoblastic leukemia (ALL), if given equal access to the most advanced therapies.

This finding--that black and white children had virtually equal rates of survival over 10 years--contrasts with the results of clinical studies from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). The POG and CCG multi-center studies showed that black children lagged behind white children in the cure rate for ALL.

Even though black children referred to St. Jude were more likely to have high-risk leukemia and be socioeconomically underprivileged, they enjoyed the same excellent treatment results as white children, according to Ching-Hon Pui, M.D., director of the St. Jude Leukemia/Lymphoma division.

Pui is senior author of this study, which appears in the Oct. 15 issue of the Journal of the American Medical Association. Despite black children presenting with more bulky disease at diagnosis and having unfavorable genetic subtypes of leukemia, the St. Jude treatment was able to achieve high cure rates that were equal in black and white children.

"It's remarkable that, although African-American children with ALL are more likely than white children to have high-risk leukemia, the black children in our studies derived as much benefit from therapy as white children," said William Evans, Pharm.D., St. Jude scientific director and a co-author of the study. "This is apparently due to the modifications we made to our previous, very successful therapies for ALL, making those treatments even more effective."

One factor contributing to the treatment success rate among black children is that all St. Jude patients received a personally tailored approached to treatment--called risk-directed therapy--regardless of health insurance s
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
14-Oct-2003


Page: 1 2

Related medicine news :

1. Both inherited traits and tumor mutations affect response to treatment of leukemia
2. Plant derivative attacks the roots of leukemia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
5. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
6. New leukemia drug shows promise in overriding all Gleevec resistance
7. Cord blood transplantation now a viable option for adult leukemia patients
8. Peptide vaccine can produce complete remission in myeloid leukemia patients
9. Methylphenidate improves attention, behavior of children surviving leukemia, brain tumors
10. Obesity linked to another cancer - leukemia in older women
11. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation

Post Your Comments:
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, the ... to lead a national chief operating officer recruitment for Nicklaus Children’s ... healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare executives ...
(Date:7/2/2015)... ... ... AvePoint Public Sector, Inc., a wholly owned subsidiary of ... it was named the recipient of the 2015 GTRA ConVurge Tech Award for Excellence ... Government Technology Research Alliance (GTRA), was presented June 29 during the ConVurge Honorary Awards ...
(Date:7/2/2015)... ... July 02, 2015 , ... As the world becomes more connected through ... they interact with products in their everyday lives. Technology can now help homeowners gain ... home entertainment and safety, as well as making kitchen tasks simpler. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... A Board ... CoolSculpting Plus, an advanced approach to body contouring. CoolSculpting Plus combines CoolSculpting® ... About the basic CoolSculpting procedure:, The CoolSculpting procedure is the only ...
(Date:7/2/2015)... ... July 02, 2015 , ... Denver-based SlimGenics Weight Control ... was named No. 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz ... been recognized. The award identifies outstanding woman-owned businesses that demonstrate excellence and success ...
Breaking Medicine News(10 mins):Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 2Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 3Health News:AvePoint Public Sector Wins 2015 GTRA ConVurge Tech Award for Excellence in Government SaaS 4Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 2Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 3Health News:KillerApps.TV Teams with Mario Armstrong to Feature Smart Home Technology 4Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 2Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 3Health News:Fort Myers Plastic Surgeon Introduces a New and Improved Body Contouring Procedure - CoolSculpting Plus™ 4Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3
(Date:7/2/2015)... Conn. , July 2, 2015 Numotion,s ... Executive Officer announced that Tamas Feitel has ... Feitel joins Numotion after a highly successful 18 year ... leadership roles driving strategy, profitability, and productivity to result ... most recent position was Chief Financial Officer for GE ...
(Date:7/2/2015)... , July 2, 2015   Decision Resources ... retinal specialists identify less frequent dosing as the ... due to the burden on both patients and ... growth factor (VEGF) injections, which are the current ... abicipar pegol, which is in development for dosing ...
(Date:7/2/2015)... The report "Silage Inoculants & Enzymes Market ... Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & Geography - ... Enzymes Market is expected to reach $489.05 Million by ... 2020. Browse 75 market Tables and ... P ages and an in-depth TOC on ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
Cached News: